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Nipah virus (NiV) infection is an upcoming zoonotic 
infection that causes medically significant disease in 
both animals and humans. The natural primary hosts 
of the virus are fruit bats (flying foxes) of the 
Pteropodidae Family and genus Pteropus.1,2 
 
Nipah virus (NiV) is a member of the family 
Paramyxoviridae, genus Henipavirus.It was initially 
identified during an outbreak of encephalitis and 
respiratory illness that took place in Kampung Sungai 
Nipah, Malaysia in 1998 where pigs were the 
intermediate hosts and the name Nipah originated 
from this place of breakout. It was back in 2004 in 
Bangladesh, when humans became infected with this 
viral disease as a result of consuming date palm sap 
already contaminated by infected fruit bats. In a 
hospital setting in India, human-to-human 
transmission has also been documented.1 
 
NiV infection in humans presents with a wide range 
of clinical symptoms, from asymptomatic infection to 
life threatening acute respiratory syndrome and even 
fatal encephalitis. The most common signs are fever, 
headache, myalgia, vomiting, dizziness, tachypnea, 
altered sensorium, convulsions, involuntary 
movements, reduced level of consciousness and 
prominent brain-stem dysfunction. It is also capable 
of infecting pigs, cats, dogs, goats, horses and other 
domestic animals.  
 
The genome of the causative agent consists of six 
genes that yield nucleoprotein, phosphoprotein, 
matrix, fusion, glycoprotein and large RNA 
polymerase and contains around 18250 nucleotides 
due to an extended open reading frame of the P gene.3 
The G and F proteins of NiV are required in mediating 
the viral entry into the cell as well as for inducing 
neutralizing antibodies.4 The P protein is the only 
essential gene product for replication of the genome 
and the additional often serve as virulence factors.5,6 
 
Infections caused by NiV in humans and animals can 
be confirmed by isolating the causative organism, 
nucleic acid amplification and serological tests like 
ELISA.   This    infection    can    also    be detected by  
molecular level diagnostic tests like Real Time-
Polymerase Chain Reaction (RT-PCR), Taqman test 
and Duplex nested RT-PCR.3 
 
Currently, there is no vaccine to prevent this disease 
in either humans or animals. Intensive supportive 
care is the mainstay of treatment in human cases. The 
key fundamental to keep a check on the outbreak and 
controlling it and reducing the morbidity/mortality 
rate is early recognition of the breakout and 
establishing preventive strategies on a preliminary 
basis. There is an essential requisite to have 
collaboration between healthcare research institutes 
and international coordination among human-
animal virologists and ecologists to thoroughly 
understand and decipher this viral epidemic. 
Concurrently there is also a requirement of 
instructing and guiding the public regarding the good 
standards of personal and food hygiene.  
 
World Health Organisation has convened a Task 
Force to formulate a strategic time based plan for the 
development of diagnostic and therapeutic 
procedures and vaccines for Nipah. The Center for 
Epidemic Preparedness and Innovation has declared 
that it will financially support the development of 
vaccines for humans against Nipah. However, until 
additional measures become available, health 
education followed by scrutiny and surveillance along 
with the outbreak response prevail to be the most 
efficacious public health tools to tackle and battle this 
disease.7 
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